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Background: PTEN is an important phosphatase, suppressing
the phosphatidylinositol-3-kinase/Akt pathway which induces
apoptosis. p27kip1 binds to cyclin-E/Cdk2 and prevents mitosis.
The inactivation of the tumor suppressor genes has been associ-
ated with many different types of cancer including the prostatic
carcinoma (PCa). In this study we investigated the influence of
an antihormonal treatment on the expression of PTEN and
p27kip1 in PCa.
Methods: 82 prostate cancer patients treated with antiandro-
gens or LH-RH analogs or a combination therapy between 1 and
77 weeks (mean 9.7 ± 1.2) were included in this study. The expres-
sion of PTEN and p27kip1 were analyzed by immunhistochemistry
and an immunreactive score. The results were compared with 183
untreated cases of a previous study.
Results: PTEN expression levels correlated with the duration of
antihormonal therapy: significantly more PTEN positive cases
were found after 3 weeks antihormonal therapy (p = 0.0003).
PTEN-expression compared to untreated tumors showed a signif-
icantly stronger PTEN-expression in treated tumors (p = 0.03). A
nuclear expression of p27kip1 was more frequent in tumors after
4 weeks of treatment compared to tumors treated less than 4
weeks (p = 0.015).
Conclusions: Both PTEN and p27kip1 expression was increased
after 4 weeks of antihormonal treatment. This fact might indicate
an early stress reaction of the tumor cells due to the androgen-
deprivation therapy.
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Background: GSK3beta is involved in the control of gene expres-
sion via the regulation of transcription factors, including estrogen
receptor alpha (ERalpha). Recently, we discovered involvement of
GSK3beta in estrogen-independent and estrogen-dependent acti-
vation of ERalpha, respectively.1,2 While phosphorylation of ERal-
pha appears to be crucial for its activation, the impact ofGSK3beta on the estrogen-dependent regulation of ERalpha func-
tion and activity remains to be clarified.
Methods: Phosphorylation of ERalpha by GSK3beta was analysed
by in vitro kinase assays. Thereafter, the effects of GSK3 inhibitors
on ERalpha phosphorylation and activation were analysed in
breast cancer cells using Western blot and luciferase reporter
assays. Further experiments using siRNA technology and trans-
fection of cells with GSK3beta mutants were performed to inves-
tigate the effects of GSK3beta regarding ERalpha signalling
pathway.
Results: In vitro kinase assays first depicted that GSK3beta phos-
phorylated ERalpha at Ser-118. Moreover, the addition of a GSK3
inhibitor (LiCl) on MCF-7 cells in culture stimulated with estradiol
(E2) led to a decrease in Ser-118 phosphorylation and to an inhibi-
tion of ERalpha-controlled luciferase activity. In agreement with
the previous observations, the knock-down of GSK3 by use of
siRNA resulted in decreased basal and E2-induced ERalpha phos-
phorylation at Ser-118 as well as in reduced luciferase activity.
Conclusion: We suggest that GSK3beta plays an important role
in the estrogen-dependent regulation of ERalpha function and
activity.
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Background: ErbB-receptors/ligands are involved in several can-
cers. Plasma cells expressing the heparin-sulphate proteoglycan
(HSPG) syndecan-1 (CD138) attach heparin-binding growth fac-
tors.1 The aim of this study is to identify new targets in the ther-
apy of multiple myeloma (MM).
Methods: Samples of 65 patients (CD138-purified MM-cells (MMC)
and bone-marrow-microenvironment (BMME)), 7 normal bone-
marrow-plasma-cell-samples (BMPC) and 20 human-myeloma-
cell-lines were studied. The expression of the 4 ErbB-receptors/
ligands on MMC and BMME will be assessed by real-time RT-PCR
and Affymetrix U133 A+B DNA-microarrays. BMME-cells from
MM-patients were exposed to PD169540 (a pan-ErbB-inhibitor)
and IRESSA (ErbB1-specific).
Results: ErbB1 and ErbB2 are expressed by BMPC, MMC and the
BMME. ErbB3 and ErbB4 are expressed by a subgroup of MMC. 7/
10 ErbB-ligands are expressed by MMC and/or the BBME. Myeloma
cell growth is stimulated by the 3 ErbB-ligands that are able to
attach HSPG (i.e amphiregulin, HB-EGF and neuregulin-1) via
binding to syndecan-1. PD169540 and IRESSA induced apoptosis
of primary MMC from 10/14 and 4/14 patients in vitro,
respectively.1,2
